Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, b-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria.
Introduction
Urinary tract infections (UTIs) are the most prevalent bacterial infection in females. The majority of UTIs in otherwise healthy women are acute uncomplicated cystitis and Escherichia coli is the most commonly isolated pathogen from UTI patients. According to the guidelines for antimicrobial use published by the IDSA and the European Society for Clinical Microbiology and Infectious Diseases in 2010, fluoroquinolones and oral cephems are alternative drugs, 1 while the first-line antimicrobial regimen for the treatment of acute uncomplicated cystitis is a 3 day regimen of fluoroquinolones in the Japanese guidelines published in 2014. 2 However, fluoroquinolone-non-susceptible E. coli is a matter of increasing concern in Japan. Recently, between 10% and 30% of E. coli strains isolated from patients with uncomplicated and complicated cystitis were resistant to fluoroquinolones. 3 Therefore, new regimens are needed for treatment of acute uncomplicated cystitis.
Cefditoren pivoxil (brand name: Meiact, Meiji Seika Pharma, Tokyo, Japan) is a third-generation oral cephalosporin with good activity against urinary tract pathogens, especially against Gram-negative bacteria. It is stable against hydrolysis by many common b-lactamases and is primarily excreted by the kidneys. 4 Cefditoren pivoxil has good clinical and antimicrobial efficacies against UTIs, respiratory tract infections and skin infections, which are approved indications in Japan. 5, 6 Therefore, cefditoren pivoxil might be effective in the treatment of antimicrobialresistant UTI-causing pathogens, including fluoroquinolonenon-susceptible E. coli. 7 However, the optimal duration of oral cephems including cefditoren pivoxil against uncomplicated cystitis has not been determined. With respect to better patient compliance, fewer adverse events, lower cost and prevention of increasing drug-resistant pathogens, shorter duration might be better. In the present study, a 3 or 7 day regimen of cefditoren pivoxil against acute uncomplicated cystitis was examined in a randomized study, by evaluating the clinical and microbiological efficacies.
Patients and methods

Study design and population
In this multicentre, randomized, open-label study, patients with symptoms of acute uncomplicated cystitis presenting during the previous week were recruited between June 2012 and May 2014 at 12 hospitals or urology clinics in Okayama Prefecture: Araki Urological Clinic (Kurashiki, Japan), Yokoyama Urological Clinic (Okayama, Japan), Miyabi Urogyne Clinic (Okayama, Japan), Hirashima Clinic (Okayama, Japan), Okayama Kyoritsu General Hospital (Okayama, Japan), Okayama University Hospital (Okayama, Japan), Okayama Saiseikai Hospital (Okayama, Japan), National Hospital Organization Okayama Medical Center (Okayama, Japan), Takahashi Central Hospital (Takahashi, Japan), Okayama City General Medical Center (Okayama, Japan), Okayama Rosai Hospital (Okayama, Japan) and Japanese Red Cross Okayama Hospital (Okayama, Japan).
The inclusion criteria included the following: female aged ≥20 years and fever ,37.58C with any cystitis symptoms, such as micturition pain, urinary frequency, urgency or lower abdominal pain with pyuria. Pyuria was defined as: ≥10 white blood cells (WBCs)/mL counted by flow cytometric analysis; ≥10 WBCs/mm 3 counted by counting chamber or a positive leucocyte esterase result using urine test paper with uncentrifuged urine; or .5 WBCs/high-power field in the sediment of centrifuged urine. Exclusion criteria were the following: occurrence of complicated UTIs; previous UTIs within 4 weeks of the current UTI; treatment with other antimicrobials within the previous 10 days; a previous episode of cephalosporin hypersensitivity; patients who had allergic asthma or hives; immunosuppression; current pregnancy; renal failure; or patients who were judged as ineligible for this study by the investigators because of low compliance. The test antimicrobial was a 100 mg cefditoren pivoxil sodium tablet, which was orally administrated three times daily (300 mg/day). Eligible patients were simply assigned to 3 or 7 day treatment groups by using random number at an internet registration centre (Clinical Research Network: MYTHOS Co. Ltd, Osaka, Japan). A dropout was recorded if catheter urine contained ,10 3 cfu/mL of live bacteria or if ,10 4 cfu/mL were detected in midstream urine.
Endpoints
Clinical and microbiological efficacies were evaluated during the second and third visits, respectively. The second visit occurred 5 -9 days after the first visit (1 day after administration of the final dose), while the third visit took place 7 -14 days following completion of cefditoren pivoxil treatment. The endpoints of this study were based on the latest clinical Japanese guidelines for urogenital infections. 2 The primary endpoint was the microbiological outcome 5 -9 days after the end of administration; effectiveness was defined as a negative urine culture (,10 3 cfu/ mL). The first of two secondary endpoints was the clinical outcome 5 -9 days after the first visit; a clinical cure was defined as the absence of symptoms. The other secondary endpoint, evaluation of recurrence 4 -6 weeks following treatment completion, was evaluated by the return of postcards on which patients wrote whether symptoms had recurred and if they had returned to the same/another clinic for treatment of any recurrence. The trial protocol is shown in Figure 1 .
Antimicrobial susceptibilities
Urine samples were collected at the first visit and 5 -9 days following treatment completion ( Figure 1 ). The MICs of amoxicillin/clavulanate, cefditoren pivoxil, faropenem, levofloxacin, minocycline and fosfomycin were measured using the broth microdilution method according to CLSI guidelines, 8 at the central laboratory (Okayama Medical Laboratory Center, Okayama, Japan). Fluoroquinolone-non-susceptible E. coli strains were defined as those with a levofloxacin MIC ≥4 mg/L. Detection of ESBL-producing E. coli strains was performed using the disc diffusion test recommended by CLSI. 9 
Statistical analysis
Continuous data including age were analysed using Student's t-test and the results presented as the mean+SD. Discrete data including clinical and microbiological efficacies and recurrence rate were expressed as percentages and compared between the two groups using Fisher's exact test by ITT analysis. The data were analysed using JMP software (v. 11; SAS, Cary, NC, USA) and P,0.05 was considered statistically significant.
Ethics
This clinical study was approved by the Okayama University Institutional Review Board prior to study initiation (registration no. 1383). The study was registered with the University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), Japan (UMIN000010449) and has been completed. The participants reviewed the informed consent document and received individual counselling with a thorough discussion as to alternative treatment, including non-participation.
Results
Study population
A total of 104 female patients were enrolled and randomized into the 3 day treatment group (3 day group; 51 patients) or 7 day 
Evaluation of microbiological and clinical efficacies
In each assignment group, there was no change of treatment regimen. The clinical cure rates of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively. The microbiological cure rate of the 3 day group was 82.5% (33/40) and it was 90.2% (37/41) for the 7 day group. There were no statistically significant differences in clinical efficacy (P ¼ 1.000; Table 2 ) or microbiological efficacy (P ¼ 0.349; Table 2 ) between the two groups.
Evaluation of recurrence
Recurrence rates at 4 -6 weeks after treatment completion were 10.2% (5/49) in the 3 day group and 12.2% (6/49) in the 7 day group. There was no statistically significant difference between the recurrence rates of the two groups (P¼ 1.000) ( Table 2 ).
Antimicrobial susceptibilities of E. coli
In total, 85 E. coli strains were isolated and 84 were examined for antimicrobial susceptibilities. MIC 50 and MIC 90 values are shown in Table 3 . Ten of 84 strains were fluoroquinolone-non-susceptible (11.9%), but revealed high susceptibility to faropenem and fosfomycin. ESBL-producing E. coli strains were detected in 7 of 84 strains (8.3%), 3 of which (42.9%) were fluoroquinolonenon-susceptible. Microbiological cure rates of patients with fluoroquinolone-non-susceptible and/or ESBL-producing E. coli strains were 90.0% (9/10) and 85.7% (6/7), respectively. In cases with an ESBL-producing E. coli strain, only one patient in the 3 day group had a recurrence (Table 4) . Cefditoren pivoxil for acute uncomplicated cystitis: RCT
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Adverse events
Neither treatment group experienced adverse events due to cefditoren pivoxil therapy, with the exception of one patient who had a mild allergic episode, which was followed by a change to a different antimicrobial.
Discussion
We compared 3 and 7 day regimens of cefditoren pivoxil administration in a multicentre, randomized, open-label study. Cefditoren pivoxil is safe and effective for the treatment of uncomplicated cystitis, with no significant differences between the two groups in clinical and microbiological efficacies. Many trials for acute uncomplicated cystitis have shown that shorter treatment regimens of fosfomycin, pivmecillinam, fluoroquinolones, trimethoprim/sulfamethoxazole or faropenem had the advantages of fewer adverse events, lower costs and better patient compliance. 10 -14 Among b-lactams, a 3 day regimen with cefpodoxime proxetil showed efficacy equivalent to that of a 3 day regimen of trimethoprim/sulfamethoxazole. 15 Some studies of Japanese patients (written in Japanese) showed that the microbiological cure rates of 3 or 7 day regimens of cefdinir, cefcapene pivoxil and cefpodoxime proxetil were 83% -98%. 16 -18 In these three studies, microbiological efficacies were evaluated immediately after administration; antimicrobials included in urine samples affected microbiological results. In the present study, microbiological cure rates using cefditoren pivoxil were 82.5% in the 3 day group and 90.2% in the 7 day group and microbiological efficacies were evaluated in urine samples 5 -9 days following administration of the final dose. The effectiveness of cefditoren pivoxil was determined to be equal to or greater than that of cefdinir, cefcapene pivoxil and cefpodoxime proxetil.
According to the guidelines in Japan, fluoroquinolones have been recommended and are the most frequently used antimicrobials for uncomplicated UTI. Furthermore, also in the USA and Europe, if there are limitations such as availability, allergic history and tolerance, fluoroquinolones and oral cephems should be used. 1 The recent surveillance of antimicrobial susceptibilities of organisms from cystitis patients showed that the proportion of fluoroquinolone-non-susceptible strains was .20% in Japan. 19 In this study, 80.0% (8/10) of fluoroquinolone-non-susceptible E. coli strains were susceptible to cefditoren pivoxil and cefditoren pivoxil was effective against uncomplicated cystitis caused by fluoroquinolone-non-susceptible E. coli strains. Furthermore, even in patients with ESBL-producing E. coli strains, the microbiological efficacy rate was 85.7% (6/7) and the non-recurrence rate was 83.3% (5/6). Despina published a paper on the antimicrobial susceptibilities of UTI pathogens to cefditoren and reported that all ESBL-producing bacteria were resistant to cefditoren pivoxil. 20 However, Teerapong et al. 21 and Sadaba et al. 22 reported on the pharmacokinetic characteristics of cefditoren pivoxil and that the primary excretion of unchanged drug into the urinary tract was 30% and that concentrations in urine samples after oral administration of cefditoren pivoxil were very high. Accordingly, the concentration of cefditoren pivoxil in urine might be higher than the MIC of cefditoren pivoxil for ESBL-producing pathogens. Our data suggest that the use of oral cephems would be an advisable regimen for the initial treatment of acute uncomplicated cystitis, even if the pathogens might be fluoroquinolone-non-susceptible and/or ESBL-producing E. coli.
With regard to the duration of administration of oral cephems for uncomplicated cystitis, some of the studies mentioned above evaluated while antimicrobials were present in urine samples, and recommended 3 day regimens rather than 4 -7 day regimens. In our study, with no impact of residual antimicrobials in urine samples, there was no significant difference between the 3 and 7 day groups in clinical and microbiological efficacies. Thus, we suggest that a 3 day treatment regimen of cefditoren pivoxil can be used as first-line therapy for acute uncomplicated cystitis in terms of clinical and microbiological efficacies.
The present study has important limitations. While there was no significant difference between the two groups in clinical and microbiological efficacies, a larger number of patients might help in detecting smaller differences. Also, there were considerable numbers of dropout patients. There was no clear pattern that suggests non-random (systematic) dropout between the two groups; therefore, we were able to assume that these dropouts did not essentially affect our results and conclusions. The consistent results for the clinical/microbiological outcomes might partly support the robustness of our study. Furthermore, one reason that there was no significant difference between the 3 and 7 day groups in clinical and microbiological efficacies might be that Gram-positive cocci including E. faecalis or S. saprophyticus were rarely detected as pathogens. Considering not only dropout cases but also pathogens for which the efficacy of cefditoren pivoxil might be low, the target number of cases should be larger. As another limitation, the aim of this study was to compare durations of cefditoren pivoxil administration, not to conduct a randomized comparison of fluoroquinolones and cephems. Thus, our data could not strongly recommend cephems rather than fluoroquinolones. Further studies comparing fluoroquinolones, cephems and other antimicrobials, such as faropenem and fosfomycin, and using the latest drug susceptibility data are necessary for the formulation of treatment recommendations for uncomplicated cystitis. As a final limitation, patients had to return a postcard to self-report on disease; therefore, we could not evaluate all patients for the recurrence of cystitis.
Conclusions
The clinical and microbiological efficacies of cefditoren pivoxil therapy for uncomplicated cystitis were assessed in this multicentre, randomized, open-label study. The efficacy rates of cefditoren pivoxil were in the same range as found in studies of other oral cephems and there was no difference in the clinical and microbiological efficacies between the 3 and 7 day regimens. Our data suggest that cefditoren pivoxil is a potent agent and a 3 day regimen might be enough for uncomplicated cystitis. Further studies are necessary to evaluate differences in duration or comparisons with other drugs.
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